Therapeutic potential of nitric oxide in cancer

被引:135
作者
Bonavida, Benjamin
Khineche, Soraya
Huerta-Yepez, Sara
Garban, Hermes
机构
[1] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
[2] Hosp Infectol, Ctr Med Nacl Raza, Inst Mexicano Seguro Social, Unidad Invest Med Immunol & Infectol, Mexico City, DF, Mexico
[3] Univ Calif Los Angeles, Dept Surg, Div Surg Oncol, David Geffen Sch Med,Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
关键词
nitric oxide sensitization; cGMP; NO donors; S-nitrosation; S-nitrosylation; NO-based therapy; cancer therapy; apoptosis;
D O I
10.1016/j.drup.2006.05.003
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
In recent years, several novel approaches have been developed to overcome tumor cell resistance to conventional therapeutics. Such approaches include genetic manipulations, vaccine development and exploitation of the anti-tumor host immune response. The overall development of tumor cell resistance to therapeutics is, in large part, the result of the ability of tumor cells to develop specific mechanisms to overcome cell death or apoptosis. Therefore, the possibility to interfere selectively in the regulation of the apoptotic signaling pathways may result in either the direct induction of cell death and/or sensitization of the cells to cytotoxic stimuli. A novel approach based on modifying Gene products that regulate resistance to apoptosis involves nitric oxide (NO). NO is a ubiquitous molecule with diverse cellular effects that depend on the source, concentration, latency, cell type and phenotype. This review describes the role played by NO in cancer including carcinogenesis, pathogenesis, angiogenesis, chemoprevention and as a novel therapeutic to overcome resistance when used alone or as a sensitizing agent used in combination with other therapeutics. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:157 / 173
页数:17
相关论文
共 158 条
[1]
Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells [J].
Ahmad, N ;
Gupta, S ;
Mukhtar, H .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 376 (02) :338-346
[2]
P53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells [J].
Ambs, S ;
Merriam, WG ;
Ogunfusika, MO ;
Bennett, WP ;
Ishibe, N ;
Hussain, SP ;
Tzeng, EE ;
Geller, DA ;
Billiar, TR ;
Harris, CC .
NATURE MEDICINE, 1998, 4 (12) :1371-1376
[3]
Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression [J].
Ambs, S ;
Hussain, SP ;
Harris, CC .
FASEB JOURNAL, 1997, 11 (06) :443-448
[4]
Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[5]
Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[6]
Nitric oxide inhibits ornithine decarboxylase via S-nitrosylation of cysteine 360 in the active site of the enzyme [J].
Bauer, PM ;
Buga, GM ;
Fukuto, JM ;
Pegg, AE ;
Ignarro, LJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (37) :34458-34464
[7]
Benz Danielle, 2002, Med Sci Monit, V8, pRA1
[8]
Bhatia GS, 2004, LANCET, V364, P1853, DOI 10.1016/S0140-6736(04)17432-1
[9]
STOP and GO with NO: nitric oxide as a regulator of cell motility in simple brains [J].
Bicker, G .
BIOESSAYS, 2005, 27 (05) :495-505
[10]
Birschmann I, 2004, ACTA BIOCHIM POL, V51, P397